NASDAQ:ACTU Actuate Therapeutics Q2 2025 Earnings Results & Report $0.45 -0.02 (-4.14%) As of 02:32 PM Eastern This is a fair market value price provided by Massive. Learn more. Actuate Therapeutics missed analyst earnings expectations in its Q2 2025 results, released August 14, 2025. The company reported EPS of -$0.30 versus the -$0.19 consensus estimate. Research:ProfileEarnings HistoryForecast Earnings Announcement Details QuarterQ2 2025Report DateAugust 14, 2025TimeAfter Market ClosesConference Call8:00 AM ET Actuate Therapeutics EPS ResultsActual EPS-$0.30Consensus EPS -$0.19Beat/MissMissed by -$0.11One Year Ago EPSN/AEPS Beat Rate3 of last 6 quartersActuate Therapeutics Revenue ResultsActual RevenueN/AExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/AConference Call ResourcesQuarterly Report (10-Q)Earnings HistoryCompany ProfilePowered by Earnings DocumentsQuarterly report(10-Q) Actuate Therapeutics Q2 2025 Earnings FAQ Did Actuate Therapeutics beat earnings estimates for Q2 2025? Actuate Therapeutics (NASDAQ:ACTU) reported earnings of -$0.30 per share for Q2 2025, missing the consensus estimate of -$0.19. The report was announced on Thursday, August 14, 2025. Actuate Therapeutics Earnings HeadlinesActuate Therapeutics (NASDAQ:ACTU) Stock Falls 6.2% - Here's WhyOctober 9, 2026 | americanbankingnews.comActuate Therapeutics' Stock Tumble on Plan to Sell 50M SharesOctober 6, 2026 | marketwatch.comHere’s Why Trump Won’t End The Iran WarTrump has called an Iran deal close 38 times since the war began, yet the fighting keeps flaring back up. One day it's a ceasefire, the next it's bombs again. The back and forth may be masking a bigger story most investors are missing. See the real reason this conflict may never fully end.October 14 at 1:00 AM | Banyan Hill Publishing (Ad)Actuate Therapeutics consensus price target decreased by 33.33% to $11.90September 15, 2026 | msn.comActuate to Present at the H.C. Wainwright 28th Annual Global Investment ConferenceSeptember 9, 2026 | globenewswire.comActuate Therapeutics: Actuate Announces Promising Preclinical Data Showing Synergistic Activity of Elraglusib in Combination with RAS Inhibitors Zoldonrasib and DaraxonrasibSeptember 9, 2026 | finanznachrichten.deSee More Actuate Therapeutics Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Actuate Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Actuate Therapeutics and other key companies, straight to your email. Email Address About Actuate TherapeuticsActuate Therapeutics (NASDAQ:ACTU) is a clinical-stage biopharmaceutical company focused on developing therapies for cancer and other serious diseases. The company’s research centers on glycogen synthase kinase-3 beta (GSK-3β), a signaling protein involved in tumor growth, inflammation and immune regulation. Actuate’s lead investigational product is elraglusib, also known as 9-ING-41, a selective small-molecule inhibitor of GSK-3β. The company has studied elraglusib in clinical programs involving hematologic malignancies and solid tumors, including acute myeloid leukemia, myelodysplastic syndromes, neuroblastoma and pancreatic cancer. Elraglusib remains an investigational therapy and has not been approved for general commercial use. Actuate is headquartered in Houston, Texas, and conducts development activities through clinical research programs and collaborations with academic and medical institutions. Publicly available information identifies Anwaar Saeed, M.D., as a senior leader associated with the company’s clinical and executive operations.View Actuate Therapeutics ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles Citi Stock Falls Despite Earnings Beat: What Investors Need to KnowDon’t Get NVIDIA’s Reflection AI Interest Wrong: Its Moat Could DeepenIREN Limited's AI Pivot Gains Traction—But Can Its Data Centers Deliver?PBF Energy's Stunning Rally Faces a Critical TestA Chinese Rival Just Spooked Memory Stocks—How Worried Should Micron Investors Be?Albertsons Is Betting on a Turnaround—But Will It Pay Off?PepsiCo's Earnings Beat Masks a Bigger Problem With Its North American Business Upcoming Earnings Interactive Brokers Group (10/15/2026)Marsh & McLennan Companies (10/15/2026)The PNC Financial Services Group (10/15/2026)Charles Schwab (10/15/2026)U.S. Bancorp (10/15/2026)Prologis (10/15/2026)Taiwan Semiconductor Manufacturing (10/15/2026)Truist Financial (10/16/2026)Travelers Companies (10/16/2026)HDFC Bank (10/17/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
